Figure 1

HIV-2 group A and group B IN polymorphisms. Polymorphisms of the HIV-2 group A IN sequences from 32 treatment-naïve and 14 treatment-experienced patients, and HIV-2 group B IN sequences from 5 treatment-naïve and 1 treatment-experienced patients are reported with respect to the ROD and EHO reference sequences respectively. Stop codons are marked with a star (*). Positions that were always polymorphic are marked with a hash (#). Positions known to confer resistance to INIs in HIV-1 or HIV-2 are indicated in red in the reference sequence; polymorphisms detected in patient sequences that are known to be associated with resistance to INIs are indicated in red, whereas polymorphisms of unknown impact at those positions are in black. For group A sequences, the frequency (percentage) of each of the polymorphisms is indicated in brackets. For group B sequences, the number of patients in which the polymorphism was detected is indicated in brackets. Only positions where variations were detected are reported. Positions mutated at least twice are highlighted in bold, except when both mutations were detected in longitudinal samples from the same patient. When all the polymorphisms in sequences from treatment-experienced patients were already present in the corresponding baseline samples, they are marked in italics; if polymorphisms in the treatment-experienced sequences are redundant with the corresponding baseline sample, they are not highlighted and counted as polymorphisms.